Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability.

Fallahi-Sichani M, Flynn JL, Linderman JJ, Kirschner DE. Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. J Immunol. 2012 Apr 01; 188(7):3169-78.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.